Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
3.365
Zitationen
20
Autoren
2017
Jahr
Abstract
Pembrolizumab was associated with significantly longer overall survival (by approximately 3 months) and with a lower rate of treatment-related adverse events than chemotherapy as second-line therapy for platinum-refractory advanced urothelial carcinoma. (Funded by Merck; KEYNOTE-045 ClinicalTrials.gov number, NCT02256436 .).
Ähnliche Arbeiten
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
2018 · 5.385 Zit.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
2016 · 3.695 Zit.
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
2001 · 3.521 Zit.
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
2015 · 3.453 Zit.
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
2016 · 3.246 Zit.
Autoren
- Joaquim Bellmunt
- Ronald de Wit
- David J. Vaughn
- Yves Fradet
- Jae‐Lyun Lee
- Lawrence Fong
- Nicholas J. Vogelzang
- Miguel Ángel Climent
- Daniel P. Petrylak
- Toni K. Choueiri
- Andrea Necchi
- Winald R. Gerritsen
- Howard Gurney
- David I. Quinn
- Stéphane Culine
- Cora N. Sternberg
- Yabing Mai
- Christian Poehlein
- Rodolfo F. Perini
- Dean F. Bajorin
Institutionen
- Dana-Farber Cancer Institute(US)
- Parc de Salut(ES)
- Radboud University Nijmegen(NL)
- Erasmus MC Cancer Institute(NL)
- Radboud University Medical Center(NL)
- Hospital del Mar Research Institute(ES)
- University of Pennsylvania(US)
- Université Laval(CA)
- Centre hospitalier universitaire de Québec(CA)
- University of Ulsan(KR)
- Asan Medical Center(KR)
- Ulsan College(KR)
- University of California, San Francisco(US)
- Comprehensive Cancer Centers of Nevada(US)
- Fundación Instituto Valenciano de Oncología(ES)
- Smilow Cancer Hospital(US)
- Yale University(US)
- Fondazione IRCCS Istituto Nazionale dei Tumori(IT)
- University Medical Center(US)
- Westmead Hospital(AU)
- Macquarie University(AU)
- USC Norris Comprehensive Cancer Center(US)
- University of Southern California(US)
- Hôpital Saint-Louis(FR)
- Nini Hospital(LB)
- Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
- Memorial Sloan Kettering Cancer Center(US)